Baxter International's Q2 2026 Earnings Call: Injectables Pressures vs. Long-Term Optimism, Margin Signals Split

Date of Call: Jul 30, 2026

Financials Results

• Revenue: $3B, up 5% on both a reported and organic basis
• EPS: $0.56 per diluted share, down 5% YOY
• Gross Margin: 38.6%, a decrease of 210 basis points
• Operating Margin: 14.2%, a decrease of 90 basis points

Guidance:

• Full-year 2026 reported sales growth expected to be 3% to 4%.
• Full-year 2026 organic sales growth expected to be 2% to 3%.
• Full-year 2026 adjusted operating margin expected to range between 13% to 14%.
• Full-year 2026 adjusted EPS guidance raised to $195 to $215 per diluted share from $185 to $205, reflecting a $75M tariff refund benefit of ~$0.11 per share.
• Expect improvement in margins in the second half of the year driven by higher volumes, cost structure benefits, and roll-through of higher cost inventory.
• Targeting ~3X net leverage by year-end 2026.

Business Commentary:

Revenue Growth and Strategic Execution:

• Baxter International reported global sales of approximately $3 billion in Q2 2026, representing an increase of 5% on both a reported and organic basis.
• The growth was driven by broad-based operational performance, particularly in advanced surgery and drug compounding, with all segments and divisions contributing.

Tariff Refund Impact and Earnings Performance:

• Adjusted earnings for Q2 were $0.56 per diluted share, reflecting a decline from $0.59 in the prior year period, but included a $75 million tariff refund benefit, which contributed approximately $0.11 per diluted share.
• The decline in earnings was primarily due to the roll-through of higher cost inventory and unfavorable prior year cost timing comparisons.

Supply Chain and Operational Improvements:

• Baxter's focus on stabilizing supply reliability across its pharmaceutical portfolio led to positive free cash flow generation of $181 million in Q2, improving sequentially from Q1.
• The company is targeting a net leverage ratio of approximately 3X by year-end, reflecting progress in strengthening its balance sheet.

Innovation and Product Launches:

• Baxter introduced PeerView, a digital benchmarking application, and launched a limited market release of the Vest APX Acute Care device, with positive early customer response.
• Continued adoption of the Connect360 platform and strong order growth in care and connectivity solutions underscored the company's innovation efforts.

Sentiment Analysis:

Overall Tone: Positive

• CEO stated 'I am encouraged by our second quarter financial results that came in ahead of expectations' and 'we are now in a stronger position to deliver on the financial goals'. Management raised full-year outlook for sales and EPS, citing 'broad-based operating performance' and 'continued steady progress on our strategic priorities'.

Q&A:

• Question from Robert Marcus (JP Morgan): Could you speak to the drivers of the acceleration on the top and bottom line and the confidence in the raised guidance? Also, given one-time items in Q2, are you still confident in growing EPS in 2027?
  Response: The Q2 beat was driven by broad-based operational improvement across segments, notably double-digit growth in drug compounding and strong demand in advanced surgery. The raised EPS guidance primarily incorporates the one-time tariff refund. While pleased with Q2, management is focused on execution in H2 2026 and will provide more color on 2027 later.

• Question from Travis Steed (Bank of America): How big was drug compounding in driving the Q2 beat, and why was the EPS guidance raised less than the Q2 beat?
  Response: Drug compounding was a 'good chunk' of the Q2 beat, growing double-digits, though it has lower margin. The EPS guidance raise was solely to include the one-time tariff refund; underlying second-half EPS expectations are consistent with prior view.

• Question from Larry Beagleson (Wells Fargo): What are the next steps for the Novum IQ LVP validation, and how durable is the Spectrum IQ as a workhorse pump if Novum is not back on the market?
  Response: Progress is being made with regulatory authorities; current Novum LVP customers are supported with mitigations. Management is confident in the total pump portfolio, including Spectrum LVP and the IQX platform, and is focused on expanding value proposition with new offerings like Peerview.

• Question from Vijay Kumar (Evercore): Were there any one-timers or restocking benefits in Q2? Also, what is the order book trend in connected care given potential hospital CapEx caution?
  Response: No material restocking benefit in IV solutions; Q2 showed broad-based strength. Demand in connected care remains stable with a strong U.S. capital order book and funnel visibility, though management continues to monitor the macro environment closely.

• Question from Peto Chickering (Deutsche Bank): What is the margin contribution of the raised organic revenue guidance, and can you detail the good and bad guys for H2 margins?
  Response: The raised sales guidance implies continued momentum at or above the 2-3% growth rate. The EPS raise is entirely due to the tariff refund. The framework for H2 margin improvement remains: higher volumes, benefits from cost actions, and cycling through higher cost inventory from 2025.

• Question from Patrick Wood (UBS): Can you unpack the strong growth in advanced surgery's hemostats and sealants? Also, will TSA income be EPS neutral in 2027?
  Response: Strong growth is due to good alignment with customers and high demand. For 2027, management is focused on executing 2026 and will provide more color later; TSA income is expected to be a net non-material impact for 2026.

• Question from Joanne Wunsch (Citi): How is the overall hospital procedure environment, and what are the gross margin expectations for the full year?
  Response: No change in customer behavior or procedure volumes has been observed. For gross margins, after normalizing for the tariff refund, sequential improvement is expected for the balance of the year, with the higher cost inventory headwind now cycled.

• Question from Rick Wise (Stiefel): What is the quantifiable impact of planned product exits on frontline care growth, and what are the growth aspirations for this business? Also, where has progress been faster than expected, and where needs to accelerate?
  Response: Planned product exits were not material. Frontline care growth is focused on strong portfolio management and launching innovations like Connex360. Progress is being driven by the accumulation of continuous improvement events (~400 completed, 200 in-flight, 400 planned) and alignment to market needs.

• Question from Matt Taylor (Jefferies): Are you seeing any impact from ACA or Medicaid changes on CapEx spending? Also, can you still assume top and earnings growth in 2027?
  Response: No significant change in customer buying behavior has been observed, but management is monitoring closely. For 2027, confidence is built through execution in 2026; more details will be provided later.

• Question from Josh Jennings (TD Cowan): What is the expected average market growth rate for Baxter's portfolio, and which business units are primed to gain share?
  Response: The overall market growth rate is viewed as low single digits. Strong performers include advanced surgery and drug compounding. Focus is on execution, innovation, and leveraging a stronger balance sheet (~3X leverage target) to drive future growth and potential tuck-in M&A.

Contradiction Point 1

Injectables & Anesthesia Business Performance and Outlook

Contradiction on the business's current state and future prospects.

Larry Biegelsen (Wells Fargo) - Larry Biegelsen (Wells Fargo)

2026Q2: The injectables & anesthesia business remains pressured due to ongoing supply constraints and softness in pre-mix products. - Andrew Hider(CEO)

What are the next steps for the Novum IQ LVP infusion pump validation, how durable is the Spectrum IQ as a workhorse if Novum doesn't return, and what is the plan to turn around the injectables and anesthesia business? - Rick Wise (Stiefel)

2026Q2: The focus is on portfolio management to drive customer value. Long-term, the business has seen improvement. - Andrew Hider(CEO)

Contradiction Point 2

Second Half Gross Margin Outlook

Contradiction on the expected trajectory and drivers of gross margin improvement.

Pito Chickering (Deutsche Bank) - Pito Chickering (Deutsche Bank)

2026Q2: The framework for H2 margin improvement remains: higher volumes, benefits from cost structure actions... and the roll-through of higher cost inventory (a headwind in H1, now a tailwind in H2). Supply chain pressures and oil price impacts are within guidance. - Kevin Moran(Investor Relations)

Can you detail the margin contributions from the raised organic revenue guidance and the factors (e.g., oil, shipping) impacting H2 margins versus previous guidance, considering the EPS raise only reflects the tariff refund? - Joanne Wuensch (Citi)

2026Q2: Gross margin was impacted in Q2 by... the roll-through of higher cost inventory (the largest headwind). This higher cost inventory has now been cycled through, and sequential improvement from Q2 (normalized for the tariff refund) is expected for the balance of the year. - Kevin Moran(Investor Relations)

Contradiction Point 3

Outlook on 2027 Earnings and Guidance Confidence

Contradiction on providing confidence or specifics for 2027 earnings growth.

Robert Marcus (JP Morgan) - Robert Marcus (JP Morgan)

2026Q2: The non-recurring tariff benefit will not flow through to 2027, and more color on 2027 will be provided later. - Andrew Heider(CEO)

What are the drivers behind the Q2 top and bottom line acceleration, confidence in the raised guidance, and implications of the EPS guide increase being less than the beat, and does 2027 EPS growth confidence remain? - Robert Marcus (JPMorgan Chase & Co)

2026Q1: While not providing 2027 guidance, expects modest growth and earnings growth as TSAs roll off. - Andrew Hider(CEO)

Contradiction Point 4

Impact and Status of Novum LVP Returns

Contradiction on quantifying the financial impact of Novum LVP returns.

Rick Wise (Stiefel) - Rick Wise (Stiefel)

2026Q2: The impact of planned product exits in Q2 was not material. - Kevin Moran(Investor Relations)

What was the impact of planned product exits on frontline care growth in Q2, what are the growth aspirations for this business moving forward, and in which areas has progress exceeded expectations versus where acceleration is needed? - Matthew Taylor (Jefferies LLC)

2026Q1: Novum return risk is not explicitly quantified but is factored into guidance; to date, impact has been immaterial. - Kevin Moran(Investor Relations)

Contradiction Point 5

Transition Services Agreement (TSA) Financial Impact and Phasing

Contradiction on TSA's earnings neutrality and phasing into 2027.

Travis Steed (Bank of America) - Travis Steed (Bank of America)

2026Q2: TSA income in Q2 was higher than expected, but this was offset by higher TSA-related expenses, resulting in no material net impact to earnings. A similar dynamic is expected for the full year. - Kevin Moran(VP, Investor Relations), Andrew Heider(CEO)

How significant was drug compounding in driving the Q2 upside, does the raised organic sales guide imply a margin trade-off given its lower margin, why was the EPS guide raised less than the Q2 beat, and how are you thinking about TSA income dynamics for next year? - David Roman (Goldman Sachs Group, Inc., Research Division)

2025Q4: We are on track to achieve a 40 basis point remaining impact for 2025, including cost takeout and TSA income. The TSAs will start to tail off in 2026, with the majority falling off in early 2027, and we are committed to eliminating stranded costs by the end of 2027. - Joel Grade(Executive VP & CFO)